Evaluation of the BCS Approximation for the Attractive Hubbard Model in One Dimension

The ground state energy and energy gap to the first excited state are calculated for the attractive Hubbard model in one dimension using both the Bethe Ansatz equations and the variational BCS wavefunction. Comparisons are provided as a function of coupling strength and electron density. While the ground state energies are always in very good agreement, the BCS energy gap is sometimes incorrect by an order of magnitude, particularly at half-filling. Finite size effects are also briefly discussed for cases where an exact solution in the thermodynamic limit is not possible. In general, the BCS result for the energy gap is poor compared to the exact result.Comment: 25 pages, 5 Postscript figure

Development of a core outcome set for traumatic brachial plexus injury

The aim of the present study was to reach international consensus on the minimum set of outcomes to measure and report in adult traumatic brachial plexus injury care and research. This would facilitate comparison of outcomes from different centres and meta-analysis in research. A list of outcomes was developed from a systematic review (n = 54) and patient interviews (n = 12). The outcomes were rated in a three-round online Delphi survey completed by international surgeons, patients and therapists. Two online consensus meetings with patients and clinicians ratified the final core outcome set. A total of 72 people (20 surgeons, 21 patients, 31 therapists) from 19 countries completed all survey rounds. Thirty-eight people from nine countries attended separate patient (n = 13) and clinician consensus (n = 25) meetings. Outcomes were included if recommended by more than 85% of contributors. Pain, voluntary movement and carrying out a daily routine are the core outcome domains that should be assessed and reported when treating and researching adults with a traumatic brachial plexus injury. Level of evidence

A study of the regulation of polyamine acetylation in human breast cancer cells

SIGLEAvailable from British Library Document Supply Centre-DSC:DXN003674 / BLDSC - British Library Document Supply CentreGBUnited Kingdo

Mon2-monocytes and increased CD-11b expression before transcatheter aortic valve implantation are associated with earlier death

Background: In the first three months after Transcatheter aortic valve implantation (TAVI), a remarkable number of patients have an unfavorable outcome. An inflammatory response after TAVI is suspected to have negative effects. The exact mechanisms remain unclear. We examined the influence of monocyte subpopulations on the clinical outcome, along with the degree of monocyte activation and further parameters of inflammation and platelet activation. Methods: Flow-cytometlic quantification analyses of peripheral blood were done in 120 consecutive patients who underwent TAVI (one day before TAVI and on day 1 and 7 after TAVI). Monocyte-subsets were defined by their CD14 and CD16 expression, monocyte-platelet-aggregates (MPA) by CD14/CD41 co-ex pression. The extent of monocyte activation was determined by quantification of CD11b-expression (activation epitope). Additionally, pro-inflammatoiy cytokines such as interleukin (IL)-6, IL-8, C-reactive protein were measured with the cytometric bead array method or standard laboratory tests. Results: Elevated Mon2 (CD14(-+)CD16(+)) - monocytes (38 vs. 62 cells/mu l, p < 0.001) and a high expression of CD11b prior to TAVI (MIL 50.1 vs. 84.6, p < 0.05) were independently associated with death 3 months after TAVI. Mon2 showed the highest CD11b-expression and CD11b correlated with platelet activation and markers of systemic inflammation. Even CRP and IL-8 before TAVI were associated with death after TAVI. In contrast, a systemic inflammation response shortly after TAVI was not associated with early death. Conclusions: Elevated Mon2-monocytes and a high level of monocyte activation before TAVI are associated with early mortality after TAVI. Chronic inflammation in aging patients seems to be an important risk factor after TAVI. (C) 2020 Elsevier B.V. All rights reserved